Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.

[1]  M. McElrath,et al.  Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial , 2022, PLoS medicine.

[2]  M. McElrath,et al.  Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa , 2021, PLoS medicine.

[3]  P. van Damme,et al.  Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol , 2021, BMJ Open.

[4]  S. Lees,et al.  Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial , 2021, The Lancet. Infectious diseases.

[5]  S. Lees,et al.  Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial , 2021, The Lancet. Infectious diseases.

[6]  H. Schuitemaker,et al.  Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate , 2020, NPJ vaccines.

[7]  Y. Lévy,et al.  Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. , 2020, The Lancet. Infectious diseases.

[8]  V. Bockstal,et al.  Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study , 2020, The Journal of infectious diseases.

[9]  S. Kapiga,et al.  Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania , 2019, The Journal of infectious diseases.

[10]  O. Anzala,et al.  Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya , 2019, The Journal of infectious diseases.

[11]  H. Schuitemaker,et al.  A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates , 2018, PloS one.

[12]  D. Bausch,et al.  Sequelae of Ebola virus disease: the emergency within the emergency. , 2016, The Lancet. Infectious diseases.

[13]  H. Schuitemaker,et al.  Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. , 2016, JAMA.

[14]  Christopher Dye,et al.  Ebola virus disease in the Democratic Republic of Congo. , 2014, The New England journal of medicine.

[15]  Stanley Lemeshow,et al.  Sample Size Determination in Health Studies: A Practical Manual , 1991 .